SCHEDULE 13G 0000919185 XXXXXXXX LIVE Common Stock, par value $0.0001 per share 06/30/2025 0001742927 REVIVA PHARMACEUTICALS HOLDINGS, INC. 76152G100 10080 N WOLFE ROAD SUITE SW3-200 CUPERTINO CA 95014 Rule 13d-1(b) HIGHBRIDGE CAPITAL MANAGEMENT, LLC DE 8000000.00 0.00 8000000.00 0.00 8000000.00 N 9.9 IA OO The shares of Common Stock (as defined in Item 2(a)) reported herein are issuable upon exercise of warrants. As more fully described in Item 4, the reported warrants are subject to the 9.9% Blocker (as defined in Item 4) and the percentage set forth on row (11) gives effect to the 9.9% Blocker. However, rows (5), (7) and (9) show the number of shares of Common Stock that would be issuable upon the full exercise of the reported warrants and does not give effect to the 9.9% Blocker. Therefore, the actual number of shares of Common Stock beneficially owned by such Reporting Person, after giving effect to the 9.9% Blocker, is less than the number of securities reported on rows (5), (7) and (9). REVIVA PHARMACEUTICALS HOLDINGS, INC. 10080 N Wolfe Road, Suite SW3-200, Cupertino, CA 95014 This statement is filed by Highbridge Capital Management, LLC ("Highbridge" or the "Reporting Person"), a Delaware limited liability company and the investment adviser to certain funds and accounts (the "Highbridge Funds"), with respect to the shares of common stock, par value $0.0001 per share ("Common Stock"), of Reviva Pharmaceuticals Holdings, Inc., a Delaware corporation (the "Issuer"), issuable upon exercise of warrants directly held by the Highbridge Funds. The filing of this statement should not be construed as an admission that any of the foregoing persons or the Reporting Person is, for the purposes of Section 13 of the Securities Exchange Act of 1934, the beneficial owner of the securities reported herein. The address of the business office of the Reporting Person is 277 Park Avenue, 23rd Floor, New York, New York 10172. Highbridge is a Delaware limited liability company. N IA The information required by Item 4(a) is set forth in Row 9 of the cover page for the Reporting Person and is incorporated herein by reference. The percentage set forth in this Schedule 13G is calculated based upon an aggregate of 68,003,613 shares of Common Stock immediately after giving effect to the completion of the Issuer's offering, as described in the Issuer's Prospectus Supplement filed pursuant to Rule 424(b)(5) with the Securities and Exchange Commission on June 26, 2025, and assumes the exercise of the warrants (the "Reported Warrants") held by the Highbridge Funds, subject to the 9.9% Blocker (as defined below). Pursuant to the terms of the Reported Warrants, the Reporting Person cannot exercise any of the Reported Warrants to the extent the Reporting Person would beneficially own, after any such exercise, more than 9.9% of the outstanding shares of Common Stock (the "9.9% Blocker") and the percentage set forth in Row (11) of the cover page for the Reporting Person gives effect to the 9.9% Blocker. Consequently, at this time, the Reporting Person is not able to exercise all of such Reported Warrants due to the 9.9% Blocker. 9.9% The information required by Item 4(c)(i) is set forth in Row 5 of the cover page for the Reporting Person and is incorporated herein by reference. The information required by Item 4(c)(ii) is set forth in Row 6 of the cover page for the Reporting Person and is incorporated herein by reference. The information required by Item 4(c)(iii) is set forth in Row 7 of the cover page for the Reporting Person and is incorporated herein by reference. The information required by Item 4(c)(iv) is set forth in Row 8 of the cover page for the Reporting Person and is incorporated herein by reference. Y N See Item 2(a). The Highbridge Funds have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the shares of Common Stock reported herein. Highbridge Tactical Credit Master Fund, L.P., a Highbridge Fund, has the right to receive or the power to direct the receipt of dividends or the proceeds from the sale of more than 5% of the shares of Common Stock. Y Y Y N By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. HIGHBRIDGE CAPITAL MANAGEMENT, LLC /s/ Kirk Rule 08/14/2025